Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Digital health technologies in clinical trials are no longer “nice to have”; they are becoming a core operating capability for participant-centered execution, decentralized elements, and faster, higher-quality data flow. This article explains which technologies matter most, how regulators frame expectations, and how to govern interoperability, data integrity, and AI responsibly.
Clinical trials are built on continuity. Recruitment may fill your pipeline, but retention keeps your study viable. When participants drop out—whether due to competing responsibilities, lack of support, or unclear
Clinical trials succeed when people stay involved. Behind every protocol and data point is a person managing their health status, daily responsibilities, and uncertainty about what participation means for them